Merlin Diamonds Limited (ASX:MED)
Credited with Australia’s largest diamond find, Merlin Diamonds (ASX:MED) is an ASX-listed sparkler still in its infancy on its way to becoming a dominant diamond producer.
MED, which has assets in the Northern Territory and Western Australia, also wields Australia’s 5 th largest diamond discovery of 35.26cts, extracted in January 2017.
The company is now ready to start production using a Tomra XRT sorter, which enables MED to recover large diamonds up to 40mm in size, which wasn’t previously possible. This means MED could once again manifest high-carat rough diamonds at a consistent rate, outscoring much larger mining operations around the globe.
A new processing plant will be able to process ore up to 40mm in size compared to the previously used 20mm. It is expected that the new processing technology will also improve diamond recovery efficiencies and costs.
MED is a diamond explorer working at the sharp end of diamond commercialisation, and its operations are gathering pace.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
MED’s decision to upgrade its processing capabilities via XRT, provides an solid opportunity for MED to recover diamonds that are larger than previously recovered in a cost-effective manner.
Here is a diamond in the rough, which will hopefully become a polished ASX jewel in the years to come.
MED Ramps Up Mining: Has its Magic Been Missed by the Market?
Aug 1, 2018
It has been a big month for Merlin Diamonds (ASX:MED), a company which has proven producing assets, an established resource, existing and increasing production and an executive chairman who has been involved in some of Australia’s largest mining projects.
Related Merlin Diamonds Limited (ASX:MED) articles
ASX Junior’s Under-Drilled Cuban Oil Asset Puts it in Multi-Billion Barrel Company
Nov 15, 2018
Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent
Nov 13, 2018